MedTrace Logo

Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients

NCT06834386 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2025-05-01

No results posted yet for this study

Summary

This phase IV trial compares suvorexant with standard of care to standard of care alone for improving difficulty sleeping (insomnia) and reducing confusion (delirium) in hospitalized cancer patients. Delirium can lengthen hospitalization, increase the delay of cancer treatment and can even increase the risk of premature death. Suvorexant is in a class of medications called orexin receptor antagonists. It works by blocking the action of a certain natural substance in the brain that causes wakefulness. Giving suvorexant with standard of care to treat insomnia may be more effective compared to standard of care alone in reducing the development of delirium in hospitalized cancer patients.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Delirium
  • Hematopoietic and Lymphatic System Neoplasm
  • Insomnia

Interventions

OTHER

Best Practice

Receive standard of care

OTHER

Electronic Health Record Review

Ancillary studies

OTHER

Interview

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Suvorexant

Given PO

Sponsors & Collaborators

Principal Investigators

  • Regina M. Mackey, MD · Mayo Clinic in Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2025-04-24
Completion
2025-04-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06834386 on ClinicalTrials.gov